Skip to main content
UNIVERSAL BIOSENSORS INC. logo

UNIVERSAL BIOSENSORS INC. — Investor Relations & Filings

Ticker · UBI ISIN · AU000000UBI2 LEI · 9845006ABC71C514C696 ASX Manufacturing
Open in API
Filings indexed 958 across all filing types
Latest filing 2024-08-20 Regulatory Filings
Country AU Australia
Listing ASX UBI

About UNIVERSAL BIOSENSORS INC.

https://universalbiosensors.com/

Universal Biosensors Inc. specializes in the research, development, and manufacture of electrochemical biosensor systems for point-of-care testing. The company leverages a proprietary technology platform to deliver rapid, accurate diagnostic results across various sectors, including healthcare and food and beverage. Its core product offerings include the Xprecia Prime system for coagulation monitoring and the Sentia platform, which provides automated laboratory-grade analysis for the wine industry, measuring parameters such as free sulfur dioxide, malic acid, and glucose. Universal Biosensors focuses on miniaturizing complex laboratory tests into portable, easy-to-use devices, utilizing multi-layer test strip architecture and sophisticated electrochemical detection methods to improve testing efficiency and accessibility in decentralized settings.

Recent filings

Filing Released Lang Actions
Italy Tender Win for Xprecia Prime 2 pages 175.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 August 2024 about a tender win in Italy for the company's product Xprecia Prime. It details the tender's value, duration, and product quantities. There is no financial data, no mention of a report or filing, no regulatory certification, no voting results, no management changes, no earnings release, and no legal or merger activity. The document is a straightforward corporate announcement about a business development (tender win). It is short (3718 characters) and does not contain financial statements or detailed analysis. Therefore, it does not fit into financial report categories like 10-K, IR, ER, or MDA. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2024-08-20 English
Universal Biosensors to host investor briefing and Q&A 2 pages 158.2KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 7 August 2024, stating that Universal Biosensors will host an investor briefing and Q&A session following the release of the company's FY24 Half Year Results. It mentions a webinar presentation of the slide deck lodged as part of the FY24 Half Year Results but does not contain the actual financial results or detailed financial data itself. The document is short (3030 characters) and serves as an announcement of an upcoming investor presentation related to the half-year results, not the report itself. Therefore, it fits the category of an Investor Presentation announcement or briefing notice. Given the content and context, the best classification is Investor Presentation (IP).
2024-08-06 English
Appendix 4D and Half Year Results - 30 June 2024 85 pages 3.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled as an Appendix 4D half year report lodged with the ASX, indicating it is a half-year financial report. It references the six months ended June 30, 2024, and includes detailed financial statements such as consolidated balance sheets, statements of comprehensive income, cash flows, and notes. It also includes a Form 10-Q, which is a quarterly report filed with the SEC, containing unaudited financial statements and management discussion and analysis. The presence of detailed financial data and the Form 10-Q strongly indicate this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is substantial and contains actual financial data, so it is not merely an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-08-01 English
Half Year Results Presentation - 30 June 2024 17 pages 723.6KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation H1 2024' and contains detailed financial and operational updates for the first half of 2024, including sales figures, gross margin, operating costs, business updates on various product lines, and strategic outlook. It includes forward-looking statements, disclaimers, and detailed charts and data typical of an investor presentation. The document is approximately 15,000 characters long, indicating it is a full presentation rather than a brief announcement. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The content aligns with the definition of an Investor Presentation (IP), which focuses on financials, strategy, and market position for investors.
2024-08-01 English
June 2024 Quarterly Activity Report and Appendix 4C 6 pages 374.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'June 2024 Quarterly Activity Report' and includes an ASX Appendix 4C cash flow report for the quarter ended 30 June 2024. It contains detailed quarterly financial data including cash flows from operating, investing, and financing activities, as well as commentary on capital raised and cash position. The presence of actual financial statements and substantive financial data for a quarter shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document is over 13,000 characters, so it is not a brief announcement or a report publication notice. It is not a full Annual Report (10-K), nor an earnings release (which would be more summary), nor a regulatory filing or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-07-29 English
UBI receives $3.8m R&D Tax Incentive Rebate 1 page
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 June 2024, stating that Universal Biosensors, Inc. has received a $3.8 million R&D Tax Incentive rebate for the 2023 financial year. The text is short (1576 characters) and focuses on announcing receipt of a government rebate, with no financial statements or detailed financial analysis included. It is not a full financial report, earnings release, or management discussion. It is a specific update on a financing-related event (receipt of a tax rebate). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-06-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.